Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
New York City Mayor Michael Bloomberg stopped by the new site of the New York Genome Center at 101 Sixth Avenue in Manhattan on Tuesday. While the center did lose out on the $100 million genius school grant last year, Bloomberg dug into his own deep coffers and offered up $2.5 million to help establish the new site.
In this video, Julia Karow, editor of In Sequence and Clinical Sequencing News, visits IMGM Laboratories in Martinsried, Germany. Ralph Oehlmann, director of business development at IMGM, gives a tour of their sequencing lab and discusses their development of metagenomic services.
BioArray News editor Justin Petrone caught up with David Ledbetter, CSO of Geisinger Health System, at the recent Annual Clinical Genetics Meeting held in Charlotte, NC, to discuss the future of CMA as a first-tier test, classifying findings of uncertain significance, and more.
The American Museum of Natural History's George Amato, director of the museum's Sackler Institute for Comparative Genomics, discusses conservation and "landscape" genetics, his PLoS One paper on the use of DNA barcoding to detect illegal bushmeat in New York-area airports, and more.
BioArray News editor Justin Petrone sat down with Shashikant Kulkarni, an associate professor at Washington University School of Medicine at St. Louis, to discuss chromosomal microarrary analysis in the clinic, SNP arrays versus CGH platforms for post-natal testing, and more.
Miragen Therapeutics' Eva van Rooij discusses microRNA-based therapeutics, the challenges associated with chronic microRNA knockdown, therapeutic microRNA antagonists, and more.
In this video, Julia Karow, Editor of Clinical Sequencing News, interviews Saskia Biskup, CEO of the Center for Genomics and Transcriptomics, or CeGaT, at the company's headquarters in Tübingen, Germany.
In this video, Illumina's CLIA laboratory manager Suneer Jain gives InSequence and Clinical Sequencing News Editor Monica Heger a tour of Illumina's CLIA lab at the company's San Diego headquarters.
Agendia CEO David Macdonald stopped by GenomeWeb's office in New York City and responded to questions from Turna Ray, editor of Pharmacogenomics Reporter, about his company's MammaPrint breast cancer recurrence test and more.
In this video, Adam Bonislawski, editor of ProteoMonitor, caught up with UCSF's Robert Chalkley at the recent Association of Biomolecular Resource Facilities meeting in Orlando, Fl. Chalkley, who is also chair of ABRF's Proteomic Informatics Research Group, discusses the challenge at this year's meeting — identifying post-translationally modified peptides in a complex background — and more.
We dropped by the Feinstein Institute for Medical Research in Manhasset, New York, for a conversation with Peter Davies, director of the Litwin-Zucker Center for the Study of Alzheimer's Disease and Memory Disorders. Davies is heading up a collaboration between the Feinstein Institute, the New York Genome Center, and Illumina that aims to uncover the genetic basis of Alzheimer's disease.
In this video, we sat down with Randall Nelson, research professor at Arizona State University's Biodesign Institute, at the Mass Spectrometry: Applications to the Clinical Laboratory 2012 meeting in San Diego. Nelson speaks about mass spectrometry immunoassay (MSIA) technology and protein heterogeneity, the challenges associated with moving mass spec into the clinic, and more.
This is part two of a conversation with Leigh Anderson, CEO of SISCAPA Assay Technologies, at the Mass Spectrometry Applications to the Clinical Laboratory 2012 meeting in San Diego, California.
Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
The Jackson Laboratory
Michael Stitzel joked that his research has led him to climb up the evolutionary tree. As an undergraduate he worked with yeast, and over the years, he has worked his way up to studying Drosophila, C. elegans, and, now, people.
Stitzel shifted from the more basic roots of the tree to the biomedical limbs as a matter of motivation. He said that as a graduate student, though he worked on an important and interesting question, when experiments didn't go well, it was hard for him to get motivated. And so, he found himself drawn to questions with more direct relevance to medicine.
He turned to studying type 2 diabetes. Using a genome-wide association study approach, he identified a number of regions in the genome linked to the disease, but many of them were, as he put it, "in the middle of nowhere." This led him to thinking about epigenetics, and then to later uncover what he and his colleagues dubbed 'stretch enhancers,' longer-than-average enhancers that appear to be driving physiological functions.
Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation
Lou, Lee, et al. Genome Biology
An international group led by investigators in Hong Kong used a combination of RNA sequencing, whole-genome bisulfite sequencing, and chromatin immunoprecipitation sequencing to quantify expression, methylation, and histone modification patterns in samples and cell lines from members of a Chinese parent-child trio affected by type 2 diabetes. Generally speaking, the researchers found that high levels of DNA methylation in the promoter region a gene correspond with lower-than-usual expression of the gene. But methylation across the gene body appeared to have a similar effect, prompting the study's authors to argue that "[f]uture studies on gene regulatory mechanisms and disease-associated differential methylation should pay more attention to DNA methylation at gene bodies and other non-promoter regions."
Gene expansion shapes genome architecture in the human pathogen Lichtheimia corymbifera: An evolutionary genomics analysis in the ancient terrestrial mucorales (Mucoromycotina)
Schwartze, Winter, et al. PLOS Genetics
The mucormycosis infection-causing fungal pathogen Lichtheimia corymbifera appears to have undergone gene duplications and genome expansions in the absence of duplications affecting the whole genome. A team from Germany, Spain, and Brazil used a combination of Roche 454 and Illumina approaches to sequence the L. corymbifera genome before comparing it to sequences from another fungal pathogen that can cause mucormycosis, called Rhizopus oryzae. The comparison indicated that the L. corymbifera genome contains a slew of duplicated genes that have taken on diverse functions, for example, but a relative lack of repeat sequences and alternative splicing.
Sanford Burnham Medical Research Institute said this week it has named Perry Nisen as its CEO and as holder of the Donald Bren Chief Executive Chair. Nisen joins Sanford Burnham from GlaxoSmithKline, where he was senior VP of science and innovation.
The New York Genome Center has named Carol Ashe its new chief business officer. She previously served as VP of corporate development for pharmaceutical firm Endo International, and prior to that was a partner at GlaxoSmithKline's venture capital fund, SR One. Ashe also led GSK's US corporate legal group, which supported M&A transactions and the business development legal transactions team.
Vermillion has named David Jansen its VP of marketing, a new position at the firm. Jansen joins Vermillion from Myriad Genetics, where he held senior marketing roles for the past seven years. Vermillion also said that Chief Commercial Officer Marian Sacco will be leaving the company as part of a reorganization and restructuring. Sacco had joined the firm just last December.
Epic Sciences has appointed Greg Lucier as chairman of its board of directors. Lucier was previously chairman and CEO of Life Technologies.